Ameera Shah-led Metropolis Healthcare Limited, India’s second-largest and most respected pathology laboratory chain, announced its unaudited consolidated financial results for the quarter ended June 30, 2025. 

The company posted Q1 FY26 revenue higher 23 per cent YoY at Rs. 386 crore. It posted PAT of Rs. 45 crore, 19% higher YoY. 

During the quarter, Patient and Test Volumes grew by 11% and 12% YoY, respectively, with B2C & B2B revenues rising 19% and 29% YoY. Revenue per Patient (RPP) and Revenue per Test (RPT) increased by 11% and 10% YoY, driven by a richer test mix, scientific upselling, and adoption of the recommendation engine. 

“Rising health awareness is fuelling demand for advanced diagnostics across prevention, wellness, and complex illness detection. These trends are expanding the formal diagnostics market and creating a broader revenue opportunities across industry players. Encouragingly, the market is stabilizing, with reduced pricing pressures and a stronger focus on clinical quality and trust. 

At Metropolis, we continue to focus on high-value and complex testing, where accuracy, scientific excellence, and deep domain expertise are critical. Our recent acquisitions have strengthened our presence in specialised diagnostics, opening up premium growth opportunities and enhancing revenue quality. 

“With sustained investments in Specialty Diagnostics, Genomics, and our Centers of Excellence, we are building a differentiated and future-ready healthcare enterprise that is well-positioned for long-term value creation,” Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited. 

Surendran Chemmenkotil, Managing Director, Metropolis Healthcare Limited, added: “We’ve begun FY26 on a strong footing, delivering 23% growth in overall revenue and a 19% increase in PAT. This growth has been driven by healthy organic momentum in our core business, supported by rising patient volumes, a stronger test mix, and improved realizations. 

“Our disciplined execution, strong cost management, and sharper commercial focus are yielding tangible results. With a comprehensive test menu and a pan-India network, we are now seeing operational efficiencies driven by our own automation and process improvements. As we move forward, our priority remains consistent execution—enhancing service quality, scaling operations effectively, and delivering sustainable, profitable growth.”